7 completed, 7 terminated, 4 recruiting, 4 withdrawn. 26 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 7, Terminated 7, Recruiting 4, Withdrawn 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 8 | Completed 3, Recruiting 2, Withdrawn 2, Terminated 1 |
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma HSK47977 - NHL | Phase 1 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 110 | 2025-08-28 | 2025-12-19 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS FD-001 - AML, NHL | Phase 1 | Recruiting | Chengdu FenDi Pharmaceutical Co., Ltd. | 72 | 2024-03-11 | 2024-12-17 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) CLN-978 - NHL, NHL, Relapsed, Adult | Phase 1 | Terminated | Cullinan Therapeutics Inc. | 3 | 2023-05-31 | 2026-10-22 |
| Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies SYNCAR-001, STK-009, Cyclophosphamide - CLL/SLL, NHL | Phase 1 | Active not recruiting | Synthekine | 36 | 2023-04-23 | 2026-07-10 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL BN102 - CLL/SLL, NHL | Phase 1 / Phase 2 | Withdrawn | BioNova Pharmaceuticals (Shanghai) LTD. | 2022-07-01 | 2023-03-24 | |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML ETH-155008 - NHL, Leukemia | Phase 1 | Terminated | Shengke Pharmaceuticals Pty Ltd | 9 | 2021-06-29 | 2023-10-11 |
| A Study of IGN002 for Refractory NHL IGN002 - NHL | Phase 1 | Withdrawn | Spectrum Pharmaceuticals, Inc | 2021-01-01 | 2022-03-11 | |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL FT596, Rituximab - NHL, Non Hodgkin Lymphoma | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 7 | 2020-09-22 | 2024-07-09 |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients IM19 CAR-T Cells - NHL | Phase 1 / Phase 2 | Recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 52 | 2020-06-04 | 2020-12-08 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies AMG 397, Dexamethasone, Azacitidine - Multiple Myeloma, Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 24 | 2018-08-17 | 2023-04-12 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) AZD9150, Acalabrutinib, AZD6738 - NHL, DLBCL | Phase 1 | Completed | Acerta Pharma BV | 30 | 2018-06-19 | 2022-08-15 |
| Safety and Efficacy Evaluation of Decitabine With R-GDP Decitabine and R-GDP - NHL | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 50 | 2017-09-01 | 2018-05-24 |
| PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) KPT-9274, Niacin ER, Nivolumab - Solid Tumors, NHL | Phase 1 | Terminated | Karyopharm Therapeutics Inc | 60 | 2016-06-08 | 2024-11-25 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies CD22-CAR - NHL, Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 134 | 2014-12-12 | 2026-04-28 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma DCR-MYC - Solid Tumors, Multiple Myeloma | Phase 1 | Terminated | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 50 | 2014-04-01 | 2024-07-11 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab - Non Hodgkin's Lymphoma, NHL | Phase 1 / Phase 2 | Withdrawn | Gilead Sciences | 2010-05-01 | 2021-08-18 |
Showing 20 of 26. Sign in to see all of them.
Lymphoma, Non-Hodgkin (13) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma (4) · Lymphoma, Follicular (4) · Multiple Myeloma (4) · Leukemia (3) · Lymphoma, B-Cell (3) · Dendritic Cell Sarcoma, Interdigitating (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Burkitt Lymphoma (1)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Lymphoma (13) · Hematologic Diseases (12) · Lymphoma, B-Cell (6) · Blood Protein Disorders (5) · Cardiovascular Diseases (5) · Hemorrhagic Disorders (5) · Hemostatic Disorders (5) · Leukemia (5)
Cyclophosphamide (3) · Rituximab (3) · fludarabine (3) · veltuzumab (2) · AZD5153 (1) · Antibodies, Monoclonal (1) · Azacitidine (1) · Biological Therapy (1) · Biopsy (1) · Decitabine (1) · Dexamethasone (1) · Drug Evaluation (1) · Echocardiography (1) · Electrocardiography (1) · Immunization, Passive (1)
Gilead Sciences (3) · Beijing Immunochina Medical Science & Technology Co., Ltd. (2) · National Cancer Institute (NCI) (2) · Acerta Pharma BV (1) · Amgen (1) · AstraZeneca (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Boston Immune Technologies and Therapeutics (1) · Cambridge Antibody Technology (1) · Chengdu FenDi Pharmaceutical Co., Ltd. (1) · Cullinan Therapeutics Inc. (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Duke University (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Hutchmed (1)
United States (17) · China (5) · Australia (3) · France (3) · Italy (2) · Poland (2) · Canada (1) · Germany (1) · Greece (1) · Israel (1) · Japan (1) · Spain (1) · United Kingdom (1)
William Wegener, MD, PhD (2) · Christopher J Melani, M.D. (1) · David Porter, MD (1) · Dr.Veronika Bachanova, MD, PhD (1) · Elizabeth Hexner, MD (1) · Hongmei Jing, MD (1) · Ian Flinn, MD, PhD (1) · James Zhang (1) · Jeffrey Skolnik, MD (1) · John Timmerman (1) · Lea Burke (1) · Mitchell Horwitz, MD (1) · Nirali N Shah, M.D. (1)
PMID 21173095, PMID 26389849, PMID 26858124, PMID 28062705, PMID 32286905, PMID 34253597, PMID 34309174, PMID 34687939, PMID 37295816, PMID 37486616, PMID 37864885, PMID 37882668, PMID 41411486, PMID 41824279
2017 (1), P01CA111412 (1)